Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.
The new price target represents a 45% upside to the stock’s closing price on Wednesday and follows the EV maker’s successful pilot launch of its robotaxis in Austin over the weekend.
The equity raise comes as Kratos expands its role in next-gen defense systems, including a new propulsion partnership with GE Aerospace and growing investor interest driven by bullish analyst coverage.
Analysts are cautiously optimistic on BlackBerry, citing stronger pipeline visibility with QNX and IoT viewed as key growth drivers after its Q1 earnings beat estimates.
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.
While many analysts on Wall Street have raised their price targets on GMS after The Wall Street Journal’s report that Home Depot may have submitted a competing bid against QXO, RBC Capital said the lack of details “raises questions.”
Analysts noted Hinge Health’s strong return on investment, rapid automation of care delivery, and profitability milestones as key drivers of their bullish stance.
RBC Bearings (NYSE:RBC) meets quality investing criteria with strong ROIC, EBIT growth, and profit quality, though its valuation remains high. A deeper look for long-term investors.
Investors are growing cautious about the timeline and payoff of Adobe’s AI initiatives, despite the company beating Q2 estimates and raising its full-year revenue forecast.
The Paris Air Show, which begins Monday, is the aviation industry’s largest trade show and typically sees several deals between aircraft manufacturers and airlines.
Starbucks Corporation (NASDAQ:SBUX) shares are moving higher on Wednesday. Analysts at RBC Capital and TD Securities weighed in on the stock. Here's what you need to know.
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of the two agents.
